A Strategic Approach to the Successful Development
of New Therapies End-to-End.

What planning and investment is required
to meet stakeholder expectations and ensure commercial success?

A panel discussion with seasoned industry experts in Investor Relations, Medical Affairs, Market Access, and Media & Public Relations

Commercial success is the ultimate goal for any company developing a new therapy. Patients must need therapy, regulators must approve it, physicians must prescribe it, and payers must pay for it. The clearer and earlier this goal guides the development, and a compelling value story is told, the higher the level of trust from stakeholders along the long road from discovery to launch. However, clarity on the path to commercial success may be limited in early development stages, and resources are certainly limited. Thus, a strategic and integrated approach end-to-end is vital.

May 9, 2023 8:00am-9:30am EDT in Boston MA

Kasia Hein-Peters

Kasia is an advisor and founder in MedTech and digital health startup companies, a mentor in two incubators (mHUB in Chicago, and StartUpNV in Las Vegas), and the founder of Abante Scientific, which offers innovation management consulting, and the SciencePreneur Academy that teaches a strategic DIVE (Discovery-Innovation-Value-Execution) framework for life science companies to create leading brands and help patients to access innovative treatments.

Read More

Anita Burrell

Anita is a dynamic, passionate and infectiously enthusiastic consultant focused on improving patient outcomes through pharmaceutical innovation, helping companies:

  • understand market dynamics and payer behavior in immunology, transplant and rare diseases

Read More

Michael Rosenblatt, M.D.

Michael’s career has been in academia, the pharma and biotech industries, and ventures. He is a physician-scientist, now advising life sciences funds, biotech and pharma companies, as well as serving on boards of directors and scientific advisory boards.

Most recently, Michael was the Chief Medical Officer of Flagship Pioneering, a Cambridge, MA-based firm that creates ...

Read More

Arne Näveke, PhD

Arne is a Communications, Advocacy and Policy executive with more than 20 years of experience in the global biotech and biopharma industries, and in non-profit. He held leading roles at Freeline Therapeutics, Inc., Alexion Pharmaceuticals, Inc. (today AstraZeneca), the International AIDS Vaccine Initiative, GSK Vaccines, Sanofi Pasteur MSD, and Aventis (today Sanofi).

Read More

Jared Holz

Jared is a Managing Director at the Mizuho Group and is the firm’s Healthcare Equity Strategist. He provides healthcare sector/single stock views and related commentary to institutional investors across all components of the industry, including therapeutics, medical devices and diagnostics and services.

Read More

Stefan Dr. Walzer, PhD

Stefan specializes in pricing, health economics, payer strategies, dossier development and submission, and negotiations since 2004. He is the founder and CEO of MArS Market Access & Pricing Strategy GmbH in Germany, and P&N – Pricing & Negotiations in Health Care, Ltd. in Canada. Stefan also co-founded mAxInsights and Kukosha AI Ltd. that use AI to support customers in their Market Access activities.

Read More



District Hall Boston

75 Northern Ave – Boston, MA 02210

Seminar – Registration

A Strategic Approach to the Successful Development of New Therapies End-to-End

Do you want to tell us something?


Stefan Dr. Walzer, PhD

Founder and CEO, MArS Market Access & Pricing Strategy GmbH – Weil am Rhein, Germany Founder and CEO, P & N – Pricing & Negotiations in Healthcare, Ltd – Toronto, Canada Co-Founder, mAxInsights, de Haarlem, The Netherlands

Arne Näveke, PhD

Owner, AN Communications, LLC, Cohasset, MA Senior Strategic Advisor, Consilium Strategic Communications, London, UK/Boston, USA Communications Executive in the global biotech and biopharma industries, and in non-profit